The publication of cardio-oncology recommendations, drafted under the aegis of the ESC, constitutes a major advance in terms of visibility, structuring and organization of care pathways.
This special file is an opportunity for the cardio-oncology group to continue the work of analyzing and disseminating these recommendations.
We will successively address the management of venous thromboembolic disease (C. Frère), the evaluation of the risk of cardiotoxicity under anti-HER2 (A. Bouali), hypertension (PY Courand), and the lengthening of the QT interval (G. Bailly) under chemotherapy.
